Can-Fite BioPharma Ltd.

Can-Fite BioPharma Ltd. is an advanced clinical-stage biopharmaceutical company that develops orally bioavailable small molecule therapeutic products. Its research and development efforts focus on treatments for cancer, liver diseases, and inflammatory conditions. The company's technology platform targets the Gi protein-associated A3 adenosine receptor, which displays elevated expression in pathological body cells compared to normal cells. Can-Fite's pipeline includes synthetic, highly specific agonists and allosteric modulators, prominently featuring drug candidates Piclidenoson, Namodenoson, and CF602. The company interacts with commercial partners and biopharmaceutical collaborators, including Ewopharma, Gebro Holding, Chong Kun Dang Pharmaceuticals, Cipher Pharmaceuticals, and Vetbiolix, through out-licensing and development agreements.

Headquartered in Ramat Gan, Israel, Can-Fite conducts its corporate and research operations in Israel while maintaining licensing relationships extending to international territories such as South Korea. The organization functions as a development-stage clinical entity without internal sales, marketing, or distribution infrastructure, utilizing dedicated laboratory and computing facilities to support its clinical trials and preclinical studies.

Summary of the business section of Can-Fite BioPharma's latest annual report, written by StockData.

“we had 5 employees, 2 of whom were employed in management and administration, 2 of whom were employed in research and development and”